Using COVID-19 and other mRNA vaccines to improve cancer immunotherapy: how they work and future possibilities

This article argues that repurposed mRNA vaccines, including COVID-19 vaccines, may help make checkpoint immunotherapy work better by reshaping the tumor immune environment.

Mechanistic commentary/review drawing on prior study findings that mRNA-lipid nanoparticle vaccination can counter tumor immune evasion and support polyclonal antitumor CD8 T-cell responses.

Because this is a perspective built on prior mechanistic and translational evidence rather than a new clinical trial, it does not directly prove efficacy in patients.